ODF2L and neoplasm: Three batches of experiments were performed using primary tumor tissues from patients 1, 5, and 10 (batch 1); patients 3 and 21 (batch 2); and patients 33 and 36 (batch 3), based on the differential expression levels of ODF2L in the primary cancer cells confirmed by Western blotting.